accumulated evidence for the safety of oral acyclovir and valacyclovir does not demonstrate an increase in the rate of major birth defects when compared with the general population or an unexposed group
topical antiviral preparations of acyclovir and penciclovir resulted in no increased rate of major birth defects during pregnancy
evidence suggests it is reasonable to offer pregnant patients either acyclovir or valacyclovir for treatment of primary or recurrent genital HSV infection, which not only treats the mother's condition, but also reduces the likelihood of transmission to the neonate, without unduly compromising fetal safety.
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page